Ozempic

News

Compounders cast adrift after semaglutide shortage ends

The FDA has said there is no longer a shortage in the US market for Novo Nordisk's GLP-1 agonist semaglutide, ending sales of compounded forms.

Digital

Looking beyond the scale: Why measures of physical activity ...

GLP-1 receptor agonists like Ozempic and Wegovy are dramatically changing how healthcare professionals approach the treatment of obesity in patients.

News

Novo rises on Wegovy sales leap, but warns of a slowdown

Novo Nordisk is expecting greater competition and pricing pressure in the obesity and diabetes sectors this year.

News

Ozempic is first GLP-1 drug FDA-approved for kidney disease

Novo Nordisk's Ozempic has become the first drug in the GLP-1 class to be cleared to prevent worsening kidney disease in type 2 diabetics.

News

Ozempic tops new Medicare price negotiation list

On their way out the door, the Biden administration has dropped the list of the next 15 drugs to be negotiated by Medicare.

News

Novo joins Lilly in asking FDA for ban on GLP-1 compounding

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made

Compounders cast adrift after semaglutide shortage ends

Looking beyond the scale: Why measures of physical activity ...

Novo rises on Wegovy sales leap, but warns of a slowdown

Ozempic is first GLP-1 drug FDA-approved for kidney disease

Ozempic tops new Medicare price negotiation list

Novo joins Lilly in asking FDA for ban on GLP-1 compounding

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Ozempic

Editor's Picks